Winston Tan, MD

Winston Tan, MD, discusses 2 agents that have advanced the treatment landscape for patients with thyroid cancer, including the multi-tyrosine kinase inhibitor lenvatinib and another TKI, sorafenib.

Winston Tan, MD, discusses the emergence of novel agents for the treatment of patients with gastrointestinal stromal tumors, namely agents like avapritinib and ripretinib, which have shown promise in ongoing clinical trials.<br /> &nbsp;

Winston Tan, MD, discusses the current treatment landscape for patients with thyroid cancer. He highlighted the importance of first determining if a patient with thyroid cancer has benign or malignant thyroid nodules, which can be identified with the use of diagnostic biopsies. He also discussed the standard-of-care treatment options for these different subtypes of patients once they are identified.

Winston Tan, MD, discusses the work of the Florida Society for Clinical Oncology, which helps improve the treatment of patients with all cancers.

The Rapid Integration Program, a training initiative for new physician&rsquo;s assistants and nurse practitioners working in the field of oncology, is a Florida Society of Community Oncology (FLASCO) initiative that came from an ASCO meeting. Winston Tan, MD, of the Head and Neck Cancer Center at the Mayo Clinic in Jacksonville, Florida, speaking during the 2019 ASCO Annual Meeting, was in attendance at the 2016 ASCO Annual Meeting when the idea for a training program was first introduced.<br /> &nbsp;